Category Archives: Patent Eligible Subject Matter

DNA Patenting “Urban Legend” Debunked At AIPLA

Posted on October 21, 2011 by Warren Woessner

The  most interesting presentation at the Annual AIPLA Meeting – which is not yet over – was Professor Christopher M. Holman’s talk – “Deconstructing the myth that 20% of  the human genome is patented” which was based on his paper … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , | Leave a comment

Myriad Petition For Rehearing Denied

Posted on September 14, 2011 by Warren Woessner

On September 13, 2011, the Fed. Cir. panel in AMP v. Myriad denied AMP’s (read ACLU’s) petition for rehearing by the panel. (A copy of the petition can be found at the end of this post.) In challenging the holding … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , , , | Leave a comment

Classen Immunotherapeutics v. Biogen Idec: Corrected Opinion Likely?

Posted on September 2, 2011 by Warren Woessner

On August 31, 2011, a three-judge panel of the Fed. Cir. (Rader, Newman, Moore) revisited the court’s 2009 summary affirmance that the claims of three Classen patents were not directed to patentable subject matter. (A copy is at the end … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , , , | 3 Comments

Cybersource Corp. v. Retail Decisions, Inc.

Posted on August 19, 2011 by Warren Woessner

  In recent posts, I have worried, then warned, the Fed. Cir. holding that the Myriad “analyzing” or “comparing” diagnostic claims were invalid as abstract ideas, would cloud the IP future of “modern” claims to personalized medicine (see posts of … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , , , | Leave a comment